The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma
Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery..
Over the past few years, the FDA has approved PD-1/L1 inhibitor for the treatment of advanced head and neck squamous cell carcinoma, involving PD-1/L1 inhibitor monotherapy, PD-1/L1 inhibitor combined with chemoradiotherapy, combined with targeted therapy, combined with neoadjuvant immunotherapy and duplex-block of immune checkpoints and so on. Herein, we briefly review the latest research results in this field, and summarize the application and efficacy of immunotherapy in the treatment of head and neck squamous cell carcinoma， which will benefits such patients to develop more precise and individualized treatment plans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery - 36(2022), 4 vom: 01. Apr., Seite 315-320 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Song, Pan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 09.05.2022 Date Revised 29.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.13201/j.issn.2096-7993.2022.04.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340402660 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340402660 | ||
| 003 | DE-627 | ||
| 005 | 20231226005130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.13201/j.issn.2096-7993.2022.04.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340402660 | ||
| 035 | |a (NLM)35511629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Song, Pan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2022 | ||
| 500 | |a Date Revised 29.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery. | ||
| 520 | |a Over the past few years, the FDA has approved PD-1/L1 inhibitor for the treatment of advanced head and neck squamous cell carcinoma, involving PD-1/L1 inhibitor monotherapy, PD-1/L1 inhibitor combined with chemoradiotherapy, combined with targeted therapy, combined with neoadjuvant immunotherapy and duplex-block of immune checkpoints and so on. Herein, we briefly review the latest research results in this field, and summarize the application and efficacy of immunotherapy in the treatment of head and neck squamous cell carcinoma， which will benefits such patients to develop more precise and individualized treatment plans | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a head and neck neoplasms squamous cell carcinoma | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Yan, Xiaoqing |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yanhui |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Yuchu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jingyi |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery |d 2007 |g 36(2022), 4 vom: 01. Apr., Seite 315-320 |w (DE-627)NLM169708233 |x 2096-7993 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:315-320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.13201/j.issn.2096-7993.2022.04.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 4 |b 01 |c 04 |h 315-320 | ||